Document is current
Any future updates will be listed below
-
Authors
Zhao, William
Nguyen, Thinh T.
Bhagwat, Atharva https://orcid.org/0009-0004-7311-0283
Kumar, Akhil https://orcid.org/0000-0001-8338-4203
Giotti, Bruno
Kepecs, Benjamin
Weirather, Jason L.
Mahadevan, Navin R.
Segerstolpe, Asa
Dolasia, Komal
Abdul-Ghafar, Jamshid https://orcid.org/0000-0002-6575-8870
Besson, Naomi R.
Jones, Stephanie M.
Soong, Brian Y. https://orcid.org/0000-0003-4647-7704
Li, Chendi
Vigneau, Sebastien
Slyper, Michal
Wakiro, Isaac
Su, Mei-Ju
Helvie, Karla
Frangieh, Allison
Jane-Valbuena, Judit
Ashenberg, Orr
Awad, Mark
Rotem, Asaf
Bueno, Raphael
Rozenblatt-Rosen, Orit https://orcid.org/0000-0001-6313-3570
Pfaff, Kathleen
Rodig, Scott
Hata, Aaron N. https://orcid.org/0000-0002-6127-318X
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Johnson, Bruce E.
Tsankov, Alexander M. https://orcid.org/0000-0002-7955-4414
-
Funding
Funding for this research was provided by:
United States Department of Defense | U.S. Army (Lung Cancer Research Program Career Development Award W81XWH2210079)
American Cancer Society (Research Scholar Grant RSG-23-1039063-01-MM)
U.S. Department of Health & Human Services | National Institutes of Health (2T32GM007280-41)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U2C CA233195, F32CA250231, U2C CA233195, U2C CA233195)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1T32GM146636)
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 26 August 2025
First Online: 7 October 2025
Competing interests
: A. Rotem is an equity holder in Celsius Therapeutics and Nucleai. A.N.H. has received research support from Amgen, Blueprint Medicines, BridgeBio, Bristol Myers Squibb, C4 Therapeutics, Pfizer, Eli Lilly, Novartis, Nuvalent, Roche/Genentech and Scorpion Therapeutics and served as a paid consultant for Engine Biosciences, Nuvalent, Oncovalent, Tolremo Therapeutics and TigaTx. R.B. has received research support from the NCI, National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung and Blood Institute and US Department of Defense and industry grants from Genentech, Roche, Merck, Siemens, NorthPond and Bicycles Therapeutics. R.B. holds equity and patents licensed to Navigation Sciences. O.R.-R. has given numerous lectures on the subject of single-cell genomics to a wide variety of audiences and, in some cases, has received remuneration to cover time and costs. A. Regev is a cofounder and equity holder of Celsius Therapeutics and an equity holder in Immunitas. A. Regev was also a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until July 31, 2020. A. Regev, O.R.-R., J.J.-V. and M.S. have been employees of Genentech since 2020 and have equity in Roche. B.E.J serves as a paid consultant to Novartis, Checkpoint Therapeutics, Astra Zeneca, Daichi Sankyo, GSK, Hummingbird Diagnostics, Genentech, Bluedot Bio, G1 Therapeutics, Jazz Pharmaceuticals, Merus, Abdera and Simcere Pharmaceutical and is a paid member of a data safety monitoring committee for Merck and Revolution Medicine. The other authors declare no competing interests.
